Irinotecan
Approved · EMAAlso known as Camptosar, Irinotecan lactone, Onivyde, (+)-Irinotecan+2 more
Camptosar, Irinotecan lactone, Onivyde, (+)-Irinotecan, Irinotecan Hydrochloride, Irinotecanum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Approval: Onivyde pegylated liposomal (previously Onivyde) (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: ONIVYDE pegylated liposomal is indicated:- in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with… Show full indicationShow less
ONIVYDE pegylated liposomal is indicated:- in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas,- in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas, in adult patients who have progressed following gemcitabine based therapy.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine5
- JAMA network open2
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2
- Anticancer research1
- Breast (Edinburgh, Scotland)1
- Cancer chemotherapy and pharmacology1
- Yoshino T3
- Ciardiello F2
- Elez E2
- Lonardi S2
- Masi G2
- Pietrantonio F2
- Tabernero J2
- Abdullah S1
- Sarah Cannon Research Institute2
- Azienda Ospedaliero-Universitaria Pisana1
- Center for Cancer Research1
- Clinical Pharmacology1
- Clinical Pharmacology Program1
- Clinical Research1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 18 of the same disease areas as Irinotecan in the shared literature.
Studied across 17 of the same disease areas as Irinotecan in the shared literature.
Studied across 12 of the same disease areas as Irinotecan in the shared literature.
Studied across 9 of the same disease areas as Irinotecan in the shared literature.
Studied across 12 of the same disease areas as Irinotecan in the shared literature.
Studied across 10 of the same disease areas as Irinotecan in the shared literature.
Studied across 8 of the same disease areas as Irinotecan in the shared literature.
Studied across 11 of the same disease areas as Irinotecan in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.